• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial.

作者信息

Shah Syed Raza, Uddin Mohd Faisal, Lateef Noman, Dharani Amin Muhammad, Shahnawaz Waqas, Kazi Ahmed Nabeel, Shah Syed Arbab

机构信息

North Florida Regional Medical Center, University of Central Florida, Gainesville, USA.

Deccan College of Medical Sciences, Hyderabad, India.

出版信息

J Community Hosp Intern Med Perspect. 2017 Jul 13;7(3):199-200. doi: 10.1080/20009666.2017.1340732. eCollection 2017 Jul.

DOI:10.1080/20009666.2017.1340732
PMID:28808518
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5538222/
Abstract
摘要

相似文献

1
Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial.依洛尤单抗降低心血管事件：（FOURIER）多国试验结果
J Community Hosp Intern Med Perspect. 2017 Jul 13;7(3):199-200. doi: 10.1080/20009666.2017.1340732. eCollection 2017 Jul.
2
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.依洛尤单抗对心血管疾病患者总体心血管事件的影响：FOURIER 试验的预先指定分析。
JAMA Cardiol. 2019 Jul 1;4(7):613-619. doi: 10.1001/jamacardio.2019.0886.
3
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.在有和没有糖尿病的患者中，PCSK9 抑制剂依洛尤单抗的心血管安全性和疗效，以及依洛尤单抗对血糖和新发糖尿病风险的影响： FOURIER 随机对照试验的预先指定分析。
Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-950. doi: 10.1016/S2213-8587(17)30313-3. Epub 2017 Sep 15.
4
Effects of Evolocumab on Cardiovascular Events.依洛尤单抗对心血管事件的影响。
Curr Cardiol Rev. 2017;13(4):319-324. doi: 10.2174/1573403X13666170918165713.
5
Inflammatory and Cholesterol Risk in the FOURIER Trial. FOURIER 试验中的炎症与胆固醇风险。
Circulation. 2018 Jul 10;138(2):131-140. doi: 10.1161/CIRCULATIONAHA.118.034032. Epub 2018 Mar 12.
6
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.在高危受试者中使用前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂进行进一步心血管结局研究的原理与设计。
Am Heart J. 2016 Mar;173:94-101. doi: 10.1016/j.ahj.2015.11.015. Epub 2015 Dec 17.
7
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.依洛尤单抗联合他汀类药物治疗稳定型动脉粥样硬化的超高危患者以预防卒中
Stroke. 2020 May;51(5):1546-1554. doi: 10.1161/STROKEAHA.119.027759. Epub 2020 Apr 21.
8
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.依洛尤单抗在 FOURIER 试验中慢性肾脏病的疗效和安全性。
J Am Coll Cardiol. 2019 Jun 18;73(23):2961-2970. doi: 10.1016/j.jacc.2019.03.513.
9
Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus.依泽替米贝与依洛尤单抗作为附加疗法用于 2 型糖尿病患者心血管事件二级预防的效果比较。
Am J Cardiol. 2019 Apr 15;123(8):1273-1276. doi: 10.1016/j.amjcard.2019.01.021. Epub 2019 Jan 23.
10
Is there enough evidence with evolocumab and alirocumab (antibodies to proprotein convertase substilisin-kexin type, PCSK9) on cardiovascular outcomes to use them widely? Evaluation of Sabatine MS, Giugliano RP, Wiviott SD et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-1509, and Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1488-99.关于依洛尤单抗和阿利西尤单抗（前蛋白转化酶枯草溶菌素9型，PCSK9的抗体）在心血管结局方面是否有足够证据支持广泛使用它们？对萨巴蒂尼MS、朱利亚诺RP、维维奥特SD等人的《依洛尤单抗降低血脂和心血管事件的疗效及安全性》（《新英格兰医学杂志》2015年；372:1500 - 1509）以及罗宾逊JG、法尔尼耶M、克雷姆夫M等人的《阿利西尤单抗降低血脂和心血管事件的疗效及安全性》（《新英格兰医学杂志》2015年；372:1488 - 1499）的评估。
Expert Opin Biol Ther. 2015;15(12):1671-5. doi: 10.1517/14712598.2015.1093109. Epub 2015 Sep 28.

引用本文的文献

1
Gigantic arteriovenous fistula between left coronary cusp and coronary sinus draining into the right atrium.左冠状动脉瓣尖与冠状窦之间存在巨大动静脉瘘，引流至右心房。
J Community Hosp Intern Med Perspect. 2021 May 10;11(3):404-406. doi: 10.1080/20009666.2021.1877398. eCollection 2021.
2
Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes.使用处方PCSK9抑制剂对心血管结局的影响。
Circ Cardiovasc Qual Outcomes. 2019 Aug;12(8):e005404. doi: 10.1161/CIRCOUTCOMES.118.005404. Epub 2019 Jul 23.
3
Using left ventricular assist devices in advanced heart failure patients.在晚期心力衰竭患者中使用左心室辅助装置。
J Community Hosp Intern Med Perspect. 2018 Dec 11;8(6):357-359. doi: 10.1080/20009666.2018.1536240. eCollection 2018.
4
Management of atrial fibrillation-flutter: uptodate guideline paper on the current evidence.心房颤动-扑动的管理：基于当前证据的最新指南文件
J Community Hosp Intern Med Perspect. 2018 Oct 15;8(5):269-275. doi: 10.1080/20009666.2018.1514932. eCollection 2018.
5
Atrial fibrillation and heart failure- results of the CASTLE-AF trial.心房颤动与心力衰竭——CASTLE-AF试验结果
J Community Hosp Intern Med Perspect. 2018 Aug 23;8(4):208-210. doi: 10.1080/20009666.2018.1495979. eCollection 2018.
6
Right ventricular dysplasia: management and treatment in light of current evidence.右心室发育不良：基于当前证据的管理与治疗
J Community Hosp Intern Med Perspect. 2018 Jun 12;8(3):101-106. doi: 10.1080/20009666.2018.1472513. eCollection 2018.

本文引用的文献

1
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
2
European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.欧洲心脏病学会/欧洲动脉粥样硬化学会工作组关于前蛋白转化酶枯草溶菌素/kexin 9型抑制剂的共识声明：用于极高心血管风险患者的实用指南。
Eur Heart J. 2017 Aug 1;38(29):2245-2255. doi: 10.1093/eurheartj/ehw480.
3
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.依洛尤单抗降低血脂和心血管事件的疗效和安全性。
N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15.
4
Recovery of myofilament function through reactivation of glycogen synthase kinase 3β (GSK-3β): mechanism for cardiac resynchronization therapy.通过糖原合酶激酶3β（GSK-3β）的再激活恢复肌丝功能：心脏再同步治疗的机制
J Interv Card Electrophysiol. 2014 Dec;41(3):193-4. doi: 10.1007/s10840-014-9939-2. Epub 2014 Sep 26.
5
Proprotein convertase subtilisin/kexin type 9 inhibition.脯氨酸内切酶枯草溶菌素/克胰蛋白酶 9 抑制剂。
Curr Opin Lipidol. 2012 Dec;23(6):511-7. doi: 10.1097/MOL.0b013e3283587563.